NEXT: New Biolimus Stent Equal to Everolimus Stent at One Year
In a match-up between biolimus-eluting stents (BES) and everolimus-eluting stents (EES), the former delivered statistically comparable one-year results, according to data from the NEXT trial presented March 10 at ACC.13.
The NEXT trial, which assigned 3,235 patients to either a BES or an EES, is the largest multicenter, randomized open-label study comparing these two devices ever reported. BES was approved in Japan in 2011, while EES is the country's leading coronary drug-eluting device. The two eluted compounds belong to the same class of drugs. The study enrolled all patients scheduled for insertion of a drug-eluting stent at 98 participating centers in Japan, with no exclusion criteria.
"Our results suggest that BES could be the alternative to EES, a current gold standard second-generation drug-eluting stent," said Masahiro Natsuaki, MD, of Kyoto University Graduate School of Medicine's Department of Cardiovascular Medicine. "Because the polymer will completely disappear one year after stent insertion, at least a three-year timeframe will be needed to demonstrate the potential advantage of BES over other available stents."
According to the study investigators, BES met the goal of non-inferiority to EES in target-lesion revascularization at one year, with target lesion revascularization in 67 BES patients vs. 66 EES patients (4.2 percent for both groups). The cumulative rates of definite stent thrombosis were low and similar at 0.25 percent in the BES group vs. 0.06 percent in the EES group. In a substudy of 528 patients, angiographic imaging confirmed similar rates of restenosis in both study arms, expressed as late lumen loss — a shrinkage of space inside the stented artery at 266 days + 43 days after the procedure: loss of 0.03+0.39mm in BES patients vs. 0.06 + 0.45 mm in EES patients.
The study's other primary outcome is death or heart attack at three years after stent insertion, with multiple secondary outcome measures for that three-year timeframe. Moving forward, interim two-year data also will be analyzed, according to the investigators.
Many patients in this study were older (mean age 69.2 + 9.8 years), had diabetes (46 percent) or already had a coronary stent (51 percent). Analysis found no differences in outcomes for these subgroups between the two stent types. An earlier study's findings had raised concerns about acute success rate with BES — the ability to deliver all intended stents to the target site and achieve the target artery diameter. In this trial, acute success rates were very high for BES and EES at 99.6 percent in both groups.
< Back to Listings